Publication:
Racial differences in neuromyelitis optica spectrum disorder

dc.contributor.authorSu Hyun Kimen_US
dc.contributor.authorMaureen A. Mealyen_US
dc.contributor.authorMichael Levyen_US
dc.contributor.authorFelix Schmidten_US
dc.contributor.authorKlemens Ruprechten_US
dc.contributor.authorFriedemann Paulen_US
dc.contributor.authorMarius Ringelsteinen_US
dc.contributor.authorOrhan Aktasen_US
dc.contributor.authorHans Peter Hartungen_US
dc.contributor.authorNasrin Asgarien_US
dc.contributor.authorJessica Li Tsz-Chingen_US
dc.contributor.authorSasitorn Sirithoen_US
dc.contributor.authorNaraporn Prayoonwiwaten_US
dc.contributor.authorHyun June Shinen_US
dc.contributor.authorJae Won Hyunen_US
dc.contributor.authorMira Hanen_US
dc.contributor.authorMaria Isabel Leiteen_US
dc.contributor.authorJacqueline Palaceen_US
dc.contributor.authorHo Jin Kimen_US
dc.contributor.otherNational Cancer Center, Gyeonggien_US
dc.contributor.otherUniversity of Oxforden_US
dc.contributor.otherCharité – Universitätsmedizin Berlinen_US
dc.contributor.otherHeinrich Heine Universitäten_US
dc.contributor.otherMax Delbruck Center for Molecular Medicineen_US
dc.contributor.otherSyddansk Universiteten_US
dc.contributor.otherQueen Elizabeth Hospital Hong Kongen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherThe Johns Hopkins School of Medicineen_US
dc.contributor.otherHumboldt-Universität zu Berlinen_US
dc.contributor.otherBiometric Research Branchen_US
dc.date.accessioned2019-08-23T11:35:51Z
dc.date.available2019-08-23T11:35:51Z
dc.date.issued2018-11-27en_US
dc.description.abstract© 2018 American Academy of Neurology. Objective We aimed to evaluate racial differences in the clinical features of neuromyelitis optica spectrum disorder. Methods This retrospective review included 603 patients (304 Asian, 207 Caucasian, and 92 Afro- American/Afro-European), who were seropositive for anti-aquaporin-4 antibody, from 6 centers in Denmark, Germany, South Korea, United Kingdom, United States, and Thailand. Results Median disease duration at last follow-up was 8 years (range 0.3-38.4 years). Asian and Afro- American/Afro-European patients had a younger onset age than Caucasian patients (mean 36, 33, and 44 years, respectively; p < 0.001). During the disease course, Caucasian patients (23%) had a lower incidence of brain/brainstem involvement than Asian (42%) and Afro-American/ Afro-European patients (38%) (p < 0.001). Severe attacks (visual acuity ≤0.1 in at least one eye or Expanded Disability Status Scale score ≥6.0 at nadir) at onset occurred more frequently in Afro-American/Afro-European (58%) than in Asian (46%) and Caucasian (38%) patients (p = 0.005). In the multivariable analysis, older age at onset, higher number of attacks before and after immunosuppressive treatment, but not race, were independent predictors of severe motor disabilities at last follow-up. Conclusion A review of a large international cohort revealed that race affected the clinical phenotype, age at onset, and severity of attacks, but the overall outcome was most dependent on early and effective immunosuppressive treatment.en_US
dc.identifier.citationNeurology. Vol.91, No.22 (2018), E2089-E2099en_US
dc.identifier.doi10.1212/WNL.0000000000006574en_US
dc.identifier.issn1526632Xen_US
dc.identifier.issn00283878en_US
dc.identifier.other2-s2.0-85057148184en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/46180
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057148184&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleRacial differences in neuromyelitis optica spectrum disorderen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057148184&origin=inwarden_US

Files

Collections